Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia
() -- Niagen Bioscience (NAGE) has received rare pediatric disease designation from the US Food and Drug Administration for NB4168 in treating ataxia telangiectasia, a multisystem disorder, the company said Monday. The European Medicines Agency also granted Orphan Medicinal Product Designation to NB4168 for the same in